Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by Wall Street Zen

Inovio Pharmaceuticals (NASDAQ:INO) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other research analysts have also weighed in on INO. HC Wainwright reissued a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday, March 19th. Royal Bank of Canada reiterated a “sector perform” rating and set a $5.00 price objective on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. Finally, Oppenheimer dropped their price objective on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.75.

Inovio Pharmaceuticals Trading Down 3.8%

Shares of INO stock opened at $2.00 on Friday. Inovio Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $12.33. The stock’s 50-day moving average price is $1.92 and its 200-day moving average price is $2.10. The stock has a market capitalization of $73.35 million, a price-to-earnings ratio of -0.63 and a beta of 1.34.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.23. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.01 million. As a group, research analysts predict that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Bank of America Corp DE increased its position in shares of Inovio Pharmaceuticals by 1,035.2% during the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company’s stock valued at $1,173,000 after purchasing an additional 584,521 shares during the last quarter. Bank of Montreal Can purchased a new position in Inovio Pharmaceuticals during the fourth quarter worth $43,000. Stonepine Capital Management LLC bought a new position in Inovio Pharmaceuticals during the fourth quarter valued at $1,922,000. Jane Street Group LLC increased its position in Inovio Pharmaceuticals by 118.2% during the fourth quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 21,512 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Inovio Pharmaceuticals by 6.4% in the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company’s stock valued at $401,000 after acquiring an additional 13,269 shares during the period. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.